Abstract
Background: Majun Brahmi (MB) and Itrifal Muqawwi Dimagh (IMD) are polyherbal Unani formulations traditionally used for the treatment of mild cognitive impairment and memory enhancement. Although they are widely used, there is no particular scientific evidence regarding the toxicity of these medicines. Objective: The present study was undertaken to evaluate the safety of MB and IMD polyherbal Unani formulation. Materials and Methods: Wistar albino rats of both genders were treated with three doses of each drug – MB and IMD, i.e., 513.88, 1027.77, and 2055.54 mg/kg body weight (bwt) orally for 14 days for acute and 90 days for subchronic oral toxicity studies. At the end of the study, bwt gain, hematology, clinical biochemistry, and histopathological examination were performed. Although no significant changes in biochemical parameters occurred at the highest dose, mild damage to the liver, kidney, and spleen was observed. Results: At the lowest dose and at the dose of 1027.77 mg/kg bwt (therapeutic effective dose [TED]) of both the drugs, no abnormalities were observed in the biochemical and hematological parameters as well as histopathological findings. Conclusion: None of the rats exhibited apparent toxicity or mortality. The results of the present study provide evidence that both the formulations are not toxic at the TED dose and hence are clinically safe.
Highlights
Among all medicine systems practiced in India, Unani medicine has emerged as an extremely popular method of alternative treatment, during the past few decades.[1]
Wistar albino rats of both genders were treated with three doses of each drug – Majun Brahmi (MB) and Itrifal Muqawwi Dimagh (IMD), i.e., 513.88, 1027.77, and 2055.54 mg/kg body weight orally for 14 days for acute and 90 days for subchronic oral toxicity studies
The present study provides evidence that both the formulations are nontoxic at the therapeutic effective dose (TED) and safe for clinical use
Summary
Among all medicine systems practiced in India, Unani medicine has emerged as an extremely popular method of alternative treatment, during the past few decades.[1]. To have wide acceptance in the international community, Unani drugs need to satisfy various criteria such as safety, efficacy, and quality when tested through contemporary scientific tools. Majun Brahmi (MB) and Itrifal Muqawwi Dimagh (IMD) are polyherbal Unani formulations traditionally used for the treatment of mild cognitive impairment and memory enhancement. They are widely used, there is no particular scientific evidence regarding the toxicity of these medicines.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
